Breaking News Instant updates and real-time market news.

BCRX

BioCryst

$7.93

-0.06 (-0.75%)

07:12
11/06/18
11/06
07:12
11/06/18
07:12

BioCryst reports Q3 EPS (28c), consensus (25c)

Reports Q3 revenue $1.45M, consensus $3.77M. Based upon development plans, merger-related incurred costs from the terminated merger agreement with Idera and awarded government contracts, BioCryst continues to expect its previously issued 2018 financial outlook to be appropriate, with net operating cash use to be in the range of $85 to $105 million, and its 2018 operating expenses to be in the range of $90 to $110 million. The company's operating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the company's stock, as well as by the vesting of the company's outstanding performance-based stock options.

  • 06

    Nov

  • 27

    Nov

BCRX BioCryst
$7.93

-0.06 (-0.75%)

10/15/18
STFL
10/15/18
INITIATION
Target $33
STFL
Buy
KalVista initiated with a Buy at Stifel
Stifel analyst Paul Matteis started KalVista Pharmaceuticals (KALV) with a Buy rating and $33 price target. The company's lead asset KVD900, an oral plasma kallikrein inhibitor, has a "realistic shot" at being a best-in-class acute therapy for hereditary angioedema, Matteis tells investors in a research note. He thinks clinical results from competitor BioCryst (BCRX) "corroborate the viability of the oral kallikrein inhibitor approach but simultaneously leave room for improvement."
09/05/18
JMPS
09/05/18
NO CHANGE
Target $16
JMPS
Outperform
BioCryst price target raised to $16 from $12 at JMP Securities
JMP Securities analyst Liisa Bayko raised her price target on BioCryst to $16 from $12 after data from the Phase 2 ZENITH-1 trial showed the liquid formulation of 750 mg BCX7353 was superior to placebo in multiple clinical outcomes measuring hereditary angioedema attacks. The data for BCX7353 opens the door to the acute treatment setting, Bayko tells investors. She maintains her Outperform rating on BioCryst shares.
08/13/18
HCWC
08/13/18
NO CHANGE
Target $13
HCWC
Buy
BioCryst price target raised to $13 from $10 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for BioCryst Pharmaceuticals (BCRX) to $13 and reiterates a Buy rating on the shares. The analyst says that based on the proxy statement of the failed merger with Idera Pharmaceuticals (IDRA) and his diligence on the treatment landscape, hereditary angioedema will continue to be a field of consolidation interest. He believes this "should add meaningful albeit less quantifiable premium" to BioCryst's valuation.
08/08/18
08/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Optinose (OPTN) initiated with an Overweight at Cantor Fitzgerald. 2. BioCryst (BCRX) reinstated with an Overweight at JPMorgan. 3. Dillard's (DDS) initiated with an Outperform at Wedbush. 4. Virtu Financial (VIRT) initiated with an Equal Weight at Morgan Stanley. 5. Assembly Biosciences (ASMB) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

SDRL

Seadrill

$14.63

-1.84 (-11.17%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Seadrill falls -11.2% »

Seadrill is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EROS

Eros International

$8.19

-1.16 (-12.41%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Eros International falls -12.4% »

Eros International is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 20

    Dec

LB

L Brands

$30.23

-4.3 (-12.45%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
L Brands falls -12.5% »

L Brands is down -12.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SCO

Scor ADR

$23.44

2.26 (10.67%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Scor ADR rises 10.9% »

Scor ADR is up 10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$45.61

4.81 (11.79%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Noah Holdings rises 11.3% »

Noah Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$11.85

1.62 (15.84%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Britannia Bulk rises 16.1% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$28.44

0.7 (2.52%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX raises FY19 revenue view to $38.6B-$38.7B from $38.2B-$38.4B »

Consensus $38.44B. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX sees Q4 revenue $10B-$10.9B, consensus $10.92B »

Says guidance assumes a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

UNP

Union Pacific

$142.91

-7.74 (-5.14%)

11:55
11/20/18
11/20
11:55
11/20/18
11:55
Options
Union Pacific put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

11:53
11/20/18
11/20
11:53
11/20/18
11:53
Conference/Events
William Blair industrial technology analysts to hold a group luncheon »

Group Luncheon Meeting to…

BECN

Beacon Roofing

$28.34

0.6 (2.16%)

11:52
11/20/18
11/20
11:52
11/20/18
11:52
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:51
11/20/18
11/20
11:51
11/20/18
11:51
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
General news
U.S. sold $50 B 4-week T-bills at a 2.20% high rate »

U.S. sold $50 B 4-week…

11:43
11/20/18
11/20
11:43
11/20/18
11:43
Conference/Events
William Blair industrials & business services analysts hold dinner meeting »

Analysts hold a year-end…

BBY

Best Buy

$63.57

1.38 (2.22%)

11:42
11/20/18
11/20
11:42
11/20/18
11:42
Recommendations
Best Buy analyst commentary  »

Best Buy 'continued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.